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Abstract 
A highly specific and sensitive radioimmunoassay for circulating human guanylin (guanylin-22-115) has been developed. Antibodies were raised 
against the amino-terminus (positions 4-16) of the peptide. Western blot analysis confirmed that the antibody selected for radioimmunoassay 
recognizes circulating high molecular weight (10.3 kDa) guanylin. Extraction and purification of guanylin from blood hemofiltrate and from blood 
plasma showed that circulating guanylin is detectable in corresponding amounts by the radioimmunoassay and by a specific bioassay. In 30 healthy 
subjects, the mean plasma concentration of immtmoreactive (IR) guanylin was 42 f 3 fmol/ml. In 22 patients with chronic renal insufficiency, the 
concentrations of IR-guanylin were significantly enhanced (1,074 + 24 fmohml), indicating that kidneys metabolize and/or eliminate the circulating 
hormone. 
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1. Introduction 
Guanylin is an endogenous hormone that activates 
intestinal guanylate cyclase (GC-C). It was initially iso- 
lated and characterized from rat jejunum as a 15 amino 
acid peptide [l]. Later it was found that guanylin circu- 
lates as a 94 amino acid peptide in human blood [2]. 
cDNA sequencing revealed that both peptides derive 
from a larger prohormone of 115 amino acids [3]: the rat 
peptide is the C-terminal end (positions 101-l 15) and the 
circulating human peptide corresponds to positions 22- 
1 15 of proguanylin. Synthetic guanylin-101-115 in- 
creases cyclic GMP content and stimulates chloride se- 
cretion in cultured intestinal epithelial (T84) cells and 
isolated rat intestinal mucosa [3,4]. These observations 
have led to the hypothesis that guanylin is involved in the 
control of intestinal fluid and electrolyte transport. 
Human guanylin-22-115 also increases cyclic GMP con- 
tent in T84 cells and stimulates chloride secretion by 
human intestinal mucosa in vitro, suggesting that the 
peptide circulating in human blood is a bioactive hormo- 
nal form of guanylin and not merely a precursor. 
Immunocytochemical studies with antibodies directed 
against different epitopes of guanylin-22-115 have 
shown that enterochromatlin (EC) cells are the cellular 
source of this hormone in the gastrointestinal tract [5]. 
This suggests that, in the gut, guanylin is a paracrine 
modulator of electrolyte transport by neighboring en- 
terocytes. It is still not known whether plasma guanylin 
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forms part of an endocrine pathway or whether it accom- 
panies intestinal paracrine secretion. As a modulator of 
intestinal chloride transport, guanylin may be involved 
in the pathophysiology of several gastrointestinal dis- 
eases, especially those with secretory diarrhea. Measure- 
ment of guanylin levels in plasma is important for a 
better understanding of the functional role of the gua- 
nylin system. Therefore, we have developed a radioim- 
munoassay for the measurement of circulating guanylin- 
22-l 15 in human plasma and initiated studies to evaluate 
the levels of immunoreactive (IR) guanylin in healthy 
subjects and patients with chronic renal failure. 
2. Materials and methods 
2.1. Peptide synthesis 
Starting from the sequence of the circulating form of human guanylin 
[2] the following peptides were synthesized: guanylin-25-37 (Gln-Asp- 
Gly-Asn-Phe-Ser-Phe-Ser-Leu-Glu-Ser-Val-Lys) and (Ty?)-guanylin- 
25-37. This sequence corresponds to a sequence near the amino-termi- 
nus (positions 416) of the circulating peptide. The peptides were 
synthesized on a Zinsser SMPS 350 automated peptide synthesizer 
using standard Fmoc chemistry [6]. Peptide chains were assembled by 
TBTUI DIPEA/HOBT activation on preloaded Wang resins. Gua- 
nylin-25-37 was synthesized as a linear peptide and as octameric multi- 
ple antigenic peptide (MAP; for immunization) [7]: MAP consists of a 
core matrix with a branched heptalysine containing eight dendritic 
chains of guanylin-25-37. Rat guanylin-101-115 was synthesized on a 
9050 peptide synthesizer (Millipore, Erkrath, FRG) on Fmoc-Cys(Trt)- 
PEG-PS-resin. A cystine bridge between residues 107 and 115 was 
introduced by oxidation with potassium ferricyanide (III), and a cystine 
bridge between residues 104 and 112 by oxidation with iodine in 5% 
acetic acid. The purity and sequence of the peptides were checked by 
reverse phase (RP)-HPLC, capillary zone electrophoresis, mass spec- 
trometry, and automated Edman degradation. 
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2.2. Immunization 
Guanylin-25-37 (MAP) was dissolved in saline (1 mg/ml) and emul- 
siiied with an equal volume of complete Freund’s adjuvant (Sigma, 
Deisenhofen, Germany). 1 ml emulsion (equivalent o 0.5 mg MAP) 
was injected subcutaneously at multiple sites on the back of 5 New 
Zealaid white rabbits. At iniervals of 4 weeks, animals were re-injected 
with 0.25 ma MAP emulsified in incomplete Freund’s adiuvant (Sigma). 
Blood for testing was withdrawn 14 diys after each bdoster injection. 
An enzyme-linked immunosorbent assay (ELISA) was used to test 
antisera for their ability to react with guanylin-25-37 (monomeric pep- 
tide). The antiserum with the highest iter (K39) was subsequently used 
in this study. 
2.3. Preparation of /‘Z511(5r)-guanylin-25-37 
(Tyrz*&guanylin&3? was radidiodinated by Immundiagnostik 
IBensheim. Germanvj usine the chloramin T method 181. 1mCi lz51 in 
a volume of 10 pl& add&l to 10 pg (Ty?)-guanyl&25-37 in 50 pl 
of 0.05 M sodium phosphate buffer, pH 7.4. The reaction was initiated 
by the addition of 10 ~1 chloramin T solution (20 pg in phosphate 
buffer). The mixture was shaken for 30 s and the reaction stopped by 
the addition of sodium metabisulfite solution (2Opg in 10 ~1 phosphate 
buffer). Sep-Pak Cl8 cartridges (Waters; Millipore) were used to 
separate labelled peptide from free ?. Specific activity was about 
700 ,&i&g. 
2.4. Radioimmunoassay procedure 
The assav buffer for RIA was 0.01 M vhosohate buffer, vH 7.4, 
containing 6.14 M NaCl, 0.01 M EDTA-d$ota&um salt (@DTA), 
0.001 M sodium acide. 0.1 mg/ml bovine serum albumin (fraction V; 
Sigma) and 0.1% Triton X-100. This assay buffer was used to dissolve 
all reagents and samples. The incubation mixture consisted of 0.1 ml 
samvle or standard (guanylin-25-37, monomeric peptide) and 0.1 ml 
K39antiserum @nal‘&lution, 1:3000). Incubation was carried out for 
24 h. followed bv addition of ‘251flvr?-auanvlin-25-37 (20.000 cvm in 
0.1 I&) and f&her incubation fb; 24’h. ‘I’hi bound and free ligands 
were separated by incubation with 0.25 ml goat anti-rabbit y-globulin 
(Immundiagnostik) with 5% polyethylene glycol (MW 6,000) for 1 h, 
and centrifugation at 2,500 x g for 20 min. The radioactivity in the 
precipitate was counted in a y-spectrometer. All procedures were per- 
formed at 4°C. The standard curve was calculated using BIB, vs. fmol 
of guanylin-25-37 (standard), see legend to Fig. 1. T’he amount of 
guanylin in the unknown samples was extrapolated from the standard 
curve linearized by a logit-log transformation. 
2.5. Purification of circulating human guanylin by RP-HPLC 
As a larger source for guanylin we used hemofiltrate collected from 
patients with chronic renal failure [9]. For purification of guanylin an 
almost identical procedure as for its isolation was used (for details, see 
[2]). In brief, hemofiltrate polypeptides were extracted with alginic acid 
according to the Mutt-Forssmann method [lo, 1 l] and the extract cor- 
responding to 3.4 1 hemofiltrate was applied to a preparative RP C4 
column (300 A, 20-45 pm, 30 x 125 mm; Parcosil; Biotek, Heidelberg, 
Germany). The absorbed pcptides were eluted with a flow rate of 5 
ml/min and fractionated with the following gradient: 0.01 N hydrochlo- 
ric acid (HCl) to 50% 2-propanol/30% methanol/O.01 N HCl in 60 min; 
2.min fractions (step 1). Aliquots of each fraction were tested in the 
bioassay with T84 cells as well as in the guanylin radioimmunoassay. 
Fractions containing bioactive and immunoreactive material were lyo- 
philized, reconstituted in 0.1% trifluoroacetic acid (TFA) and re-chro- 
matographed on a Parcosil RP C4 column (250 A, 2&45 pm, 20 x 125 
mm): gradient from 30% acetonitrile. 0.1% TFA to 80% acetonitrile, 
0.16 YFA in 100 min; flow rate, 3 &/min, 2-min fractions (step 2). 
Again, aliquots of all HPLC fractions were assayed for bioactive and 
immunoreactive guanylin. 
2.6. Detection of guanylin bioactivity 
The increase in cyclic GMP content in human colon carcinoma cells 
(T84, passages 20-26; ATCC, Rockville, MD) was used as a sensitive 
detection system for bioactive guanylin as described [2]. 
2.7. Western blot analysis 
For immunoblots, 5% aliquots (v/v) of all HPLC fractions were 
lyophilized and resuspended in sample buffer with 4% SDS (Merck, 
Darmstadt, Germany), 50 mM Tris-HCl, pH 8.45, 1 mM EDTA, 
3.24 mM dithiothreitol (DTT; Roth, Karlsruhe, Germany), 12.5% glyc- 
erol (w/v) (Merck) and 0.002% Bromphenol blue (Merck) and incu- 
bated for 7 min at 95°C (reducing conditions). The samples were sepa- 
rated by tricine-SDS-PAGE in 17.5% gels [12]. The low Mw markers 
from Boehringer-Mannheim (Mannheim, Germany) were used for the 
Mw calibration. After electrophoresis, proteins were electroblotted 
onto hydrophobic polyvinylidene difluoride (PVDF).based membranes 
(Pall, Dreieich, Germany). To block non-specific binding of the anti- 
bodies, blot strips were incubated in 5% skim milk in Tris-buffered 
saline containing 10 mM Tris and 150 mM NaCl (PH 8.0) with 0.05% 
Tween 20 (TBST). After washing in TBST the membranes were incu- 
bated overnight at 4°C with K39 antiserum (1: 1,000). Immunoreactive 
proteins were visualized after incubation with alkaline phosphatase- 
conjugated goat antibody to rabbit IgG (1:8,000) (Sigma) using Nitro- 
blue tetrazolium and 5-bromo-4.chloro-3-indoylphosphate s chromo- 
gens (Sigma). Proteins remaining in the gels were fixed in 30% methanol 
and 10% acetic acid for 45 min before they were stained with Coomassie 
brilliant blue in 10% acetic acid for l-2 h. 
2.8. Plasma and urine extraction 
Plasma samples were obtained from 30 healthy individuals (17 men, 
13 women, aged 19-69 yrs, mean 47 yrs) and from 22 patients with renal 
insufficiency undergoing chronic hemodialysis (13 men, 9 women, aged 
4&73 yrs, mean 62 yrs). 10 ml blood samples were withdrawn into 
ice-chilled tubes containing K,EDTA and centrifuged at 2,500 x g for 
20 min at 4°C. 2 ml aliquits bf plasma were diluted 1:l with 0.01 N 
HCl and adiusted to vH 3.0 with concentrated HCl. The samples were 
applied to iep-Pak 618 cartridges (Waters) preactivated with metha- 
nol. The columns were washed with 0.01 N HCl and the absorbed 
materials were eluted with 2 ml of 30% 2.propanoY3046 methanol/O.01 
N HCl. 1 ml aliquots of the eluents (corresponding to 1 ml plasma) were 
lyophiliid and reconstituted for RIA and bioassay. Urine samples (5 
ml) of 6 healthy volunteers were extracted with Sep-Pak Cl 8 cartridges 
following the same procedure as detailed for plasma. 
2.9. Statistics 
Statistical differences between mean values were determined by anal- 
vsis of variance followed bv the Fisher vrotected least significant differ- 
ence test for comparison o-f different means. P values of less than 0.05 
were considered significant. 
3. Results 
A standard curve produced by a plot of the percentage 
of bound counts (B) divided by the zero standard (B,J vs. 
the log concentration of guanylin-25-37 is shown in Fig. 
1. The minimum detectable quantity of guanylin-25-37 
was 3.1 fmol/tube (96% displacement). The binding of 
[‘251](Ty?“)-guanylin-25-37 in the absence of unlabelled 
guanylin-25-37 (zero standard, B,,) was 26 + 1.4% (n = 8 
assays). The concentration producing 50% inhibition of 
binding was 200 fmol/tube. The intra- and inter-assay 
coefficients of variation were 6 and 14%, respectively. The 
antiserum did not show any cross-reaction with other 
known cyclic GMP-enhancing peptides (CDD/ ANP-99- 
126, BNP, C-type natriuretic peptide and urodilatin) nor 
with other peptide hormones such as angiotensin I and 
II, endothelin-1, pituitary adenylate cyclase activating 
peptide (PACAP)- and PACAP-38, vasoactive intesti- 
nal peptide (VIP), neuropeptide Y, neurokinins A and B, 
substance P, neurotensin, bradykinin or bombesin. The 
maximum concentration tested to reveal cross-reactivity 
of these peptides was 1 nmol/tube (10 pmol/l). 
To characterize the specificity of the RIA further, cir- 
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Fig. 1. Radioimmunoassay (RIA) for circulating human guanylin. 
Standard curve for guanylin-25-37 (0, mean f S.E.M., n = 8) and 
crossreactivities with natriuretic peptides (CDD/ANP-99-126, BNP, 
CNP, urodilatin: A). Dilution curve of normal human plasma extract 
(0); serial dilutions of original plasma volume are denoted under the 
curve. The results are expressed as the percentage of bound counts (B) 
divided by the zero standard (I&,). 
mofiltrate using nearly identical conditions as for its ini- 
tial isolation [2]. After extraction of polypeptides with 
the alginic acid method of Mutt-Forssmann [ 10,111, the 
material was chromatographed on a preparative RP C4 
column (step 1). Fraction aliquots were tested in the T84 
cell bioassay and in the RIA. Representative HPLC pro- 
files of blood hemofiltrate extract are shown in Fig. 2. 
The guanylin- RIA reactivity in the fractions showed two 
distinct peaks. The major component eluted in the posi- 
tion of guanylin-22-115, between 83 and 88% buffer B 
(elution time for guanylin-22-115 known from the isola- 
tion procedure [2]). The minor component eluted earlier, 
between 66 and 73% buffer B (step 1, Fig. 2). Both com- 
ponents led to marked increases in cyclic GMP content 
of T84 cells (Fig. 2). Fractions containing guanylin-22- 
115 (fractions 15-18) were re-chromatographed on a 
semi-preparative RP C4 column. Again, bioactive and 
immunoreactive guanylin co-eluted in the same fractions 
between 53 and 58% buffer B (step 2, Fig. 2). 
In each bioassay the cyclic GMP response of T84 cells 
to the hemofiltrate fractions was compared to their re- 
sponse to synthetic guanylin-101-115 (1 nM-10 PM) 
(Fig. 2). The HPLC fractions exhibited corresponding 
bioactivity with respect to their concentrations of IR- 
guanylin. This correlation was already obtained in the 
second HPLC step. As an example, in this step, fraction 
30 contained the highest concentration of bioactive as 
well as immunoreactive guanylin. The concentration of 
IR-guanylin was 34.8 pmol/ml (34.8 nM). In the bioas- 
say, 1 ml of fraction 30 evoked a 27-fold increase in cyclic 
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GMP content of T84 cells. For comparison, in the same 
experiment, 100 nM synthetic guanylin-101-115 induced 
a 44-fold increase in cyclic GMP content of T84 cells 
(Fig. 2). 
In parallel experiments, aliquots of all HPLC fractions 
were separated by tricine-SDS-PAGE and immunoblot- 
ted. The tricine electrophoresis ystem was preferred to 
conventional SDS-PAGE because of its higher resolu- 
tion of low Mw proteins, especially in the range between 
5 and 20 kDa [12]. Western blot analyses howed that the 
peptide predominantly recognized by the K39 antiserum 
was in the range of 10-l 1 kDa (Mw of circulating human 
guanylin, 10.3 kDa). The main immunoreactive peptide 
was present only in lanes loaded with HPLC fractions 
step 1
Fig. 2. Representative chromatograms obtained during puritkation of 
human guanylin from hemofiltrate. HPLC conditions are given in sec- 
tion 2. (B), eluent B (96, v/v). Columns indicate the immunoreactive and 
bioactive fractions (open columns, RIA; hatched columns, bioassay). 
At the right of the graphs is given the concentration-dependent stimu- 
lation of cyclic GMP content in T84 cells by rat guanylin-101-115 
(guanylin: 1 nM-10 PM). 
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Fig. 3. Western blots after tricine-SDS-PAGE of HPLC-fractionated 
human hemo6ltrate (steps 1 and 2). Positions of fraction aliquots are 
indicated on the top. Immunostaining was with K39 antisem against 
guanylin-25-37 (1: 1,000). The migration positions of molecular weight 
markers (Boehringer-Mannheim) are shown on the left of the blot (20.1, 
trypsin inhibitor; 12.5, cytochrome c; and 6.5, aprotinin). Note the 
prominent immunoreactive band below 12 kDa in the lanes corre- 
sponding to fractions 16-18 (step 1) and fractions 29-31 (step 2). 
containing guanylin according to the bioassay and RIA 
(step 1, fractions 16-18; step 2, fractions 29-31) (Fig. 3). 
The identity of this main immunoreactive band as gua- 
nylin-22-115 was further suggested from the fact that the 
same peptide band (in identical HPLC fractions) was 
labeled by other guanylin antisera directed against a 
midportion (positions 13-25: antiserum K42) and 
against he C-terminal end (antiserum K605) of circulat- 
ing human guanylin (data not shown; for details of the 
antisera, see [5]). In addition, the immunoblot with K39 
antiserum showed minor immunoreactive bands above 
20 kDa. These weakly stained bands were also present 
in HPLC fractions that did not contain measurable gua- 
nylin neither by bioassay nor by RIA, suggesting that 
they were due to non-specific cross-reactions of the K39 
antiserum in the immunoblot which, however, do not 
interfere in the RIA. 
The RIA was applied to measure guanylin concentra- 
tions in Sep-Pak-extracted human plasma. The dilution 
curves generated from human plasma extracts paralleled 
that of standard guanylin-25-37 (Fig. 1). The mean con- 
centration of IR-guanylin in plasma of 30 healthy sub- 
jects was 42 + 3.1 fmol/ml (mean + S.E.M. range, 25-66 
fmol/ml). In plasma collected from 22 patients under- 
going dialysis because of severe renal insufficiency, levels 
of IR-guanylin were significantly increased up to 
1,074 f 24 fmol/ ml (P < 0.05). 
Resting cyclic GMP content of T84 cells in the pres- 
ence of isobutylmethylxanthine (IBMX, 1 mM) was 
362 + 23 fmollwell (n = 4) 60-min incubation of T84 cells 
with the 0.4 ml plasma extracts of healthy subjects 
(n = 11) increased cyclic GMP content to 480 f 60 fmol/ 
well (not significant). In contrast, the 0.4 ml plasma ex- 
tracts of dialysis patients (n = 12) led to 3-7 fold in- 
creases in cyclic GMP content of T84 cells (1,760 f 360 
fmol/well, P < 0.05). We were also able to detect IR- 
guanylin in urine. The mean concentration of IR-gua- 
nylin in urine extracts of six healthy subjects was 95 + 18 
fmol/ml. The urine extract (0.4 ml; incubation time, 60 
min) induced 7-12 fold increases in cyclic GMP content 
of T84 cells (3,390 + 530 fmol/well, n = 6, P < 0.01). 
4. Discussion 
A sensitive RIA for the main circulating molecular 
form of human guanylin has been developed. A minimal 
concentration of 3.1 fmol/tube can be detected, thus ena- 
bling us to measure IR-guanylin in human plasma. The 
antigen for immunization was a peptide containing posi- 
tions 416 of the circulating hormone. Immunization 
with a MAP was chosen because the conventional step 
of conjugation of peptide to carrier can be omitted and 
because of the higher immunogenicity of MAPS in com- 
parison to the corresponding monomeric peptide [7]. The 
antiserum used for RIA (K39) recognizes guanylin- 
MAP (Western blot, not shown), monomeric guanylin- 
25-37 (ELISA, RIA) and, more importantly, native cir- 
culating human guanylin-22-115 (Western blot). It 
shows no crossreaction with a large series of other circu- 
lating hormones tested, in particular with other cyclic 
GMP-stimulating peptides. 
After extraction of polypeptides from blood hemofil- 
trate and subsequent fractionation by RP-HPLC, the 
assay of the obtained fractions for immunoreactive gua- 
nylin correlates with the detection of cGMP-stimulating 
material in the T84 cell bioassay. With both assays gua- 
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nylin-22-115 is detected in the same fractions and in 
comparable concentration ranges. However, in contrast 
to the bioassay, the RIA is more sensitive and allows the 
exact quantification of guanylin. Its sensitivity is more 
than two orders of magnitude higher than that of the 
bioassay (detection limits: RIA, 3 fmol/i.T.; bioassay, 1 
pmol/well). In the first RP-HPLC step of blood hemofil- 
trate, besides guanylin-22-115 an additional peak of 
bioactive and immunoreactive material was detected. 
Further HPLC purification steps confirmed the corre- 
spondence between RIA and bioassay also for this sec- 
ond component (data not shown). It should be empha- 
sized that in this context other known guanylyl cyclase- 
stimulating peptides (CDD/ANP-99-126, BNP, CNP, 
Urodilatin) do not interfere either with the RIA or the 
bioassay (i.e. these peptides do not alter cyclic GMP 
content of T84 cells). Therefore, we postulate that a sec- 
ond hormonal form of guanylin circulates in human 
blood. Presently, investigations are being carried out to 
characterize its precise molecular identity. 
Application of this RIA allows for the first time the 
detection of guanylin in human plasma. Levels of im- 
munoreactive guanylin in plasma of healthy subjects are 
in the range of 25-66 fmol/ml, i.e. far below the concen- 
trations that can be detected by the T84 cell bioassay. In 
our institute, blood hemotiltrate obtained from renal- 
insufficient patients is an established source for the isola- 
tion of human plasma peptides. Actually, circulating 
human guanylin was isolated from this source [2]. For 
that reason we were interested in the evaluation of gua- 
nylin plasma levels in renal insufficient patients. In all 
patients, plasma concentrations of IR-guanylin are in- 
creased l&20 fold (range: 0.5-2 nM/l). The guanylin 
bioassay confirms this observation: extracted plasma of 
these patients causes a 3-7 fold increase in cyclic GMP 
content of T84 cells. Similar increases are induced by 
0.6-l nM/l guanylin-101-115. 
Enhanced levels of IR and bioactive guanylin in 
plasma of dialysis patients indicate that the kidneys are 
involved in the metabolism and/or elimination of the 
hormone. In fact, we also detect guanylin in urine. How- 
ever, in urine, guanylin bioactivity is disproportionately 
high compared to concentrations of IR-guanylin. Pub- 
lished data suggest that the C-terminal end of the 
hormone carries the active (GC-C stimulating) domain 
[l]. A possible explanation for our findings is that circu- 
lating guanylin-22-115 is filtered and metabolized (pro- 
teolized) in the kidney, and therefore urine contains bio- 
active C-terminal fragments of guanylin that cannot be 
detected by RIA. Recently, uroguanylin, a guanylin 
homologue peptide, was isolated from opossum urine 
[13]. Although the presence of this peptide in urine from 
other species has not been described until now, we can- 
not exclude the possibility that human urine may contain 
other guanylyl cyclase C-stimulating peptides that escape 
detection by the presented RIA. 
Despite the enhanced plasma levels of guanylin, none 
of the dialysis patients included in our study had diar- 
rhea or other gastrointestinal disorders. This suggests 
that the hormone, once circulating in blood does not 
reach its intestinal receptor at the luminal side of the 
enterocytes. 
In ongoing studies the levels of IR-guanylin in patients 
with several gastrointestinal disorders, especially those 
patients with intestinal diarrhea, are being investigated 
further. Also, a major focus of our studies is the compar- 
ison between IR-guanylin in plasma and intestinal fluid 
secretion. The results will indicate whether circulating 
IR-guanylin levels reflect intestinal release, and hope- 
fully will contribute to a clarification of the pathophysi- 
ological role of this hormone in disturbances of intestinal 
electrolyte transport. 
Acknowledgements: We thank Mrs. Regine Wehking and Mr. Wolfgang 
Posselt for their expert technical assistance. 
References 
[l] Currie, M.G., Fok, K.F., Kato, J., Moore, R.J., Hamra, F.K., 
Duff&, K.L. and Smith, C.E. (1992) Proc. Natl. Acad. Sci. USA 
89,947-951. 
[2] Kuhn, M., Raida, M., Adermann, K., Schulz-Knappe, P., Gerzer, 
R., Heim, J.-M. and Forssmann, W.G. (1993) FEBS Lett. 318, 
205-209. 
[3] Wiegand, R.C., Kato, J., Huang, M.D., Fok, K.F., Kachur, J.F. 
and Currie, M.G. (1992) FEBS Lett. 311, 150-154. 
[4] Forte, L.R., Eber, S.L., Turner, J.T., Freeman, R.H., Fok, K.F. 
and Currie, M.G. (1993) J. Clin. Invest. 91, 2423-2428. 
[5] Cetin, Y., Kuhn, M., Kulaksiz, H., Adermann, K., Bargsten, G., 
Grube, D. and Forssmann, W.G. (1994) Proc. Natl. Acad. Sci. 
USA (in press). 
[6] Atherton, E. and Sheppard, R.C. (1989) in: Solid Phase Peptide 
Synthesis (D. Rickwood and B.D. Hames, eds.) IRL Press at 
Oxford University Press. 
[A Tam, J.P. (1988) Proc. Natl. Acad. Sci. USA 85, 5409-5413. 
[8] Hunter, W.M. and Greenwood, EC. (1962) Nature 194,495-496. 
[9] Forssmann, W.G., Schulz-Knappe, P., Meyer, M., Adermann, K., 
Forssmann, K., Hock, D. and Aoki, A. (1993) in: Proceedings of 
the 2nd Japan Symposium on Peptide Chemistry (N. Yanaihara 
ed.) pp. 553-557, Escom, L&den. 
[lo] Mutt, V. (1978) in: Gut Hormones (Bloom, S.R. ed.) pp. 21-27, 
Churchill Livingstone, Edinburgh. 
[ll] Forssmann, K., Hock, D., Herbst, F., Schulz-Knappe, P., 
Talartschik, J., Scheler, F. and Forssmann, W.G. (1986) Klin. 
Wochenschr. 64, 12761289. 
[12] Schagger, H. and von Jagow, G. (1987) Anal. Biochem. 166,368- 
379. 
[13] Hamra, F.K., Forte, L.R., Eber, S.L., Pidhorodeckyj, N.V., 
Krause, W.J., Freeman, R.H., Chin, D.T., Tompkins, J.A., Fok, 
K.F., Smith, C.E., Duffin, K.L., Siegel, N.R. and Currie, M.G. 
(1993) Proc. Natl. Acad. Sci. USA 90, 1046410468. 
